Candesartan and Hydrochlorothiazide contains 2 medications: candesartan and hydrochlorothiazide. Candesartan belongs to a family of medications known as angiotensin II receptor blockers. Hydrochlorothiazide belongs to a family of medications known as diuretics (or "water pills"). This combination medication is used to lower high blood pressure.

The global Candesartan and Hydrochlorothiazide market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Candesartan and Hydrochlorothiazide volume and value at global level, regional level and company level. From a global perspective, this report represents overall Candesartan and Hydrochlorothiazide market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Candesartan and Hydrochlorothiazide in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Candesartan and Hydrochlorothiazide manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
AstraZeneca
ANI Pharmaceuticals
TEVA
Mylan
Dr. Reddy's Laboratories
Zydus Pharmaceuticals
Prinston Pharmaceutical
MACLEODS

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
16/12.5
32/12.5
32/25

Segment by Application
Adult
Geriatric